{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T02:44:08Z","timestamp":1774579448497,"version":"3.50.1"},"reference-count":63,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T00:00:00Z","timestamp":1757894400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>To develop and validate a dynamic clinical prediction model integrating prostate-specific antigen (PSA) and peripheral blood biomarkers for distinguishing benign from malignant prostate diseases in patients with elevated PSA levels.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A retrospective study was conducted of clinicopathological data and preoperative blood specimen information of patients who underwent ultrasound-guided prostate biopsy in The First Affiliated Hospital of Zhejiang Chinese Medical University due to elevated PSA between January 2018 and November 2024.Univariate analysis, Least Absolute Shrinkage and Selection Operator regression, and multifactorial logistic regression analysis were utilized to identify independent risk factors associated with benign or malignant prostate disease in patients with elevated PSA (PSA &amp;gt; 4.0ng\/ml). The construction of a clinical prediction model was then undertaken, with the subsequent calibration and integration into a network calculator.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 529 patients were included based on predefined inclusion and exclusion criteria, comprising 268 (50.7%) with benign pathology and 261 (49.3%) with malignancy. After analysis, independent risk factors associated with benign or malignant prostatic diseases in patients with elevated PSA levels were identified, including PSA, white blood cell, neutrophil-to-lymphocyte ratio, lymphocyte-to-monocyte ratio, eosinophil count, basophil count, and serum albumin. Utilizing these independent risk factors, a clinical prediction model for the risk of PSA-elevated prostate benign-malignant disease was constructed, yielding an area under the curve of 0.906, a predictive model specificity of 77.6%, and a sensitivity of 95%. The calibration curve and clinical decision curve indicated that the model exhibited superior calibration ability. A dynamic prediction model was formulated based on the clinical prediction model integrated into a network calculator.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study establishes a non-invasive prediction model integrating PSA and peripheral blood biomarkers, providing a clinically practical tool for risk stratification in patients with elevated PSA levels.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2025.1599266","type":"journal-article","created":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T04:12:29Z","timestamp":1757909549000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Development and validation of a prostate cancer risk prediction model for the elevated PSA population"],"prefix":"10.3389","volume":"15","author":[{"given":"Junhui","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaodong","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiali","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingqian","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenkai","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nengfeng","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yubing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiasheng","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junlong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenhao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1097\/JU.0000000000003491","article-title":"Early detection of prostate cancer: AUA\/SUO guideline part I: prostate cancer screening","volume":"210","author":"Wei","year":"2023","journal-title":"J Urol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2015.05.032","article-title":"Prostate health index and prostate cancer gene 3 score but not percent-free Prostate Specific Antigen have a predictive role in differentiating histological prostatitis from PCa and other nonneoplastic lesions (BPH and HG-PIN) at repeat biopsy.) at repeat biopsy","volume":"33","author":"De Luca","year":"2015","journal-title":"Urol Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2004.10.064","article-title":"Evidence suggesting PSA cutpoint of 2.5 ng\/mL for prompting prostate biopsy: review of 36,316 biopsies","volume":"65","author":"Gilbert","year":"2005","journal-title":"Urology"},{"key":"B5","volume-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer","author":"Cornford","year":"2025"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2024.0455","article-title":"Development and validation of an 18-gene urine test for high-grade prostate cancer","volume":"10","author":"Tosoian","year":"2024","journal-title":"JAMA Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-023-00765-0","article-title":"Concerns regarding prostate cancer screening guidelines in minority populations","volume":"27","author":"Sweis","year":"2024","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.4103\/aja.aja_55_19","article-title":"Prostate cancer risk prediction models in Eastern Asian populations: current status, racial difference, and future directions","volume":"22","author":"He","year":"2020","journal-title":"Asian J Androl"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.21037\/tau-20-1151","article-title":"Biomarkers for detection of clinically significant prostate cancer: contemporary clinical data and future directions","volume":"10","author":"Eyrich","year":"2021","journal-title":"Transl Androl Urol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr.2019.11.16","article-title":"Prognostic biomarkers in stage IV non-small cell lung cancer (NSCLC): neutrophil to lymphocyte ratio (NLR), lymphocyte to monocyte ratio (LMR), platelet to lymphocyte ratio (PLR) and advanced lung cancer inflammation index (ALI)","volume":"8","author":"Mandaliya","year":"2019","journal-title":"Transl Lung Cancer Res"},{"key":"B11","article-title":"NLR, PLR, LMR and MWR as diagnostic and prognostic markers for laryngeal carcinoma","volume":"14","author":"Li","year":"2022","journal-title":"Am J Transl Res"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2280002","DOI":"10.1080\/07853890.2023.2280002","article-title":"Predictive value of immunotherapy-induced inflammation indexes: dynamic changes in patients with nasopharyngeal carcinoma receiving immune checkpoint inhibitors","volume":"55","author":"Cao","year":"2023","journal-title":"Ann Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"208","DOI":"10.7150\/ijbs.27537","article-title":"Establishing a prediction model for prostate cancer bone metastasis","volume":"15","author":"Chen","year":"2019","journal-title":"Int J Biol Sci"},{"key":"B14","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.neo.2021.11.004","article-title":"Cholesterol and saturated fatty acids synergistically promote the Malignant progression of prostate cancer","volume":"24","author":"Wang","year":"2022","journal-title":"Neoplasia"},{"key":"B15","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1017\/S0007114512005119","article-title":"A consideration of biomarkers to be used for evaluation of inflammation in human nutritional studies","author":"Calder","year":"2013","journal-title":"Br J Nutr"},{"key":"B16","doi-asserted-by":"publisher","first-page":"6275","DOI":"10.3390\/ijms24076275","article-title":"Physiological rhythms and biological variation of biomolecules: the road to personalized laboratory medicine","volume":"24","author":"Coskun","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0236445","article-title":"Inflammatory markers for predicting overall survival in gastric cancer patients: A systematic review and meta-analysis","volume":"15","author":"Kim","year":"2020","journal-title":"PloS One"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1126\/science.1232227","article-title":"Neutralizing tumor-promoting chronic inflammation: a magic bullet","volume":"339","author":"Coussens","year":"2013","journal-title":"Science"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.867516","article-title":"Neutrophil extracellular traps (NETs) promote non-small cell lung cancer metastasis by suppressing lncRNA MIR503HG to activate the NF-\u03baB\/NLRP3 inflammasome pathway","volume":"13","author":"Wang","year":"2022","journal-title":"Front Immunol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"15827","DOI":"10.3390\/ijms232415827","article-title":"Diverse neutrophil functions in cancer and promising neutrophil-based cancer therapies","volume":"23","author":"Sounbuli","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-023-00600-4","article-title":"CD8(+) T cells maintain killing of MHC-I-negative tumor cells through the NKG2D-NKG2DL axis","volume":"4","author":"Lerner","year":"2023","journal-title":"Nat Cancer"},{"key":"B22","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s12943-021-01428-1","article-title":"Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives","volume":"20","author":"Mao","year":"2021","journal-title":"Mol Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1454124","article-title":"Predictive diagnostic value of mean platelet volume to platelet count and neutrophil to lymphocyte ratios in the gray zone of prostate cancer with tPSA between 4 to 10 ng\/mL","volume":"14","author":"Yi","year":"2024","journal-title":"Front Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000005307","article-title":"Predictive value of neutrophil-to-lymphocyte ratio in diagnosis of prostate cancer among men who underwent template-guided prostate biopsy: A STROBE-compliant study","volume":"95","author":"Huang","year":"2016","journal-title":"Med (Baltimore)"},{"key":"B25","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1159\/000494259","article-title":"Neutrophil, platelets, and eosinophil to lymphocyte ratios predict gleason score upgrading in low-risk prostate cancer patients","volume":"102","author":"Ferro","year":"2019","journal-title":"Urol Int"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.5489\/cuaj.3550","article-title":"Role of neutrophil-to-lymphocyte ratio in prediction of Gleason score upgrading and disease upstaging in low-risk prostate cancer patients eligible for active surveillance","volume":"10","author":"Gokce","year":"2016","journal-title":"Can Urol Assoc J"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajur.2022.02.007","article-title":"Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios alone or combined with prostate-specific antigen for the diagnosis of prostate cancer and clinically significant prostate cancer","volume":"10","author":"Nepal","year":"2023","journal-title":"Asian J Urol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000027244","article-title":"Predictive value of the monocyte-to-lymphocyte ratio in the diagnosis of prostate cancer","volume":"100","author":"Xu","year":"2021","journal-title":"Med (Baltimore)"},{"key":"B29","doi-asserted-by":"publisher","first-page":"820","DOI":"10.3390\/jcm12030820","article-title":"Diagnostic efficiency of pan-immune-inflammation value to predict prostate cancer in patients with prostate-specific antigen between 4 and 20 ng\/mL","volume":"12","author":"Zhu","year":"2023","journal-title":"J Clin Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2024.1372731","article-title":"Association between monocyte-to-lymphocyte ratio and prostate cancer in the U.S. population: a population-based study","volume":"12","author":"Wang","year":"2024","journal-title":"Front Cell Dev Biol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.25143","article-title":"Prediction of prostate cancer from routine laboratory markers with automated machine learning","volume":"39","author":"Sat\u0131r","year":"2025","journal-title":"J Clin Lab Anal"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.7314\/APJCP.2015.16.15.6407","article-title":"Predictive value of the platelet-to-lymphocyte ratio in diagnosis of prostate cancer","volume":"16","author":"Yuksel","year":"2015","journal-title":"Asian Pac J Cancer Prev"},{"key":"B33","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1186\/s12894-024-01617-2","article-title":"Investigation of association between clinically significant prostate cancer, obesity and platelet-to-lymphocyte ratio and neutrophil -to-lymphocyte ratio","volume":"24","author":"Dahan","year":"2024","journal-title":"BMC Urol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"e1327","DOI":"10.1002\/iid3.1327","article-title":"Associations of systemic immune-inflammation index with high risk for prostate cancer in middle-aged and older US males: a population-based study","volume":"12","author":"Yao","year":"2024","journal-title":"Immun Inflammation Dis"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.3390\/jpm11111231","article-title":"Evaluation of the predictive role of blood-based biomarkers in the context of suspicious prostate MRI in patients undergoing prostate biopsy","volume":"11","author":"Rajwa","year":"2021","journal-title":"J Pers Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.7314\/APJCP.2013.14.8.4779","article-title":"Subtypes of white blood cells in patients with prostate cancer or benign prostatic hyperplasia and healthy individuals","volume":"14","author":"Cihan","year":"2013","journal-title":"Asian Pac J Cancer Prev"},{"key":"B37","doi-asserted-by":"publisher","first-page":"3140","DOI":"10.3390\/biomedicines11123140","article-title":"Inflammation in prostate cancer: exploring the promising role of phenolic compounds as an innovative therapeutic approach","volume":"11","author":"Fernandes","year":"2023","journal-title":"Biomedicines"},{"key":"B38","article-title":"Activated eosinophils upregulate the metastasis suppressor molecule E-cadherin on prostate tumor cells","volume":"49","author":"Furbert-Harris","year":"2003","journal-title":"Cell Mol Biol (Noisy-le-grand)"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.2174\/0929867323666160119094313","article-title":"Eosinophils in cancer: favourable or unfavourable","volume":"23","author":"Sakkal","year":"2016","journal-title":"Curr Med Chem"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.2008.02958.x","article-title":"Eosinophils: biological properties and role in health and disease","volume":"38","author":"Hogan","year":"2008","journal-title":"Clin Exp Allergy"},{"key":"B41","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.jaci.2018.10.064","article-title":"Intravenous immunoglobulin induces IL-4 in human basophils by signaling through surface-bound IgE","volume":"144","author":"Galeotti","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-021-09815-0","article-title":"Clinical outcomes and immune metrics in intratumoral basophil-enriched gastric cancer patients","volume":"28","author":"He","year":"2021","journal-title":"Ann Surg Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.177.10.7322","article-title":"Expression and functions of the vascular endothelial growth factors and their receptors in human basophils","volume":"177","author":"de Paulis","year":"2006","journal-title":"J Immunol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1593\/neo.12724","article-title":"Identification of basophils as a major source of hepatocyte growth factor in chronic myeloid leukemia: a novel mechanism of BCR-ABL1-independent disease progression","volume":"14","author":"Cerny-Reiterer","year":"2012","journal-title":"Neoplasia"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.5173\/ceju.2013.02.art3","article-title":"Low pre-operative levels of serum albumin predict lymph node metastases and ultimately correlate with a biochemical recurrence of prostate cancer in radical prostatectomy patients","volume":"66","author":"Sejima","year":"2013","journal-title":"cent Eur J Urol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-19-1525","article-title":"Hematologic markers and prostate cancer risk: A prospective analysis in UK biobank","volume":"29","author":"Watts","year":"2020","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2023.1078280","article-title":"The relationship between serum albumin and prostate-specific antigen: an analysis of the National Health and Nutrition Examination Survey, 2003-2010","volume":"11","author":"Xu","year":"2023","journal-title":"Front Public Health"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.13766","article-title":"HALP score and albumin levels in men with prostate cancer and benign prostate hyperplasia","volume":"75","author":"Kaya","year":"2021","journal-title":"Int J Clin Pract"},{"key":"B49","doi-asserted-by":"publisher","first-page":"513","DOI":"10.3390\/ph15050513","article-title":"An albumin-binding PSMA ligand with higher tumor accumulation for PET imaging of prostate cancer","volume":"15","author":"Ren","year":"2022","journal-title":"Pharm (Basel)"},{"key":"B50","doi-asserted-by":"publisher","first-page":"11501","DOI":"10.3390\/ijms231911501","article-title":"Prognostic value of albumin to globulin ratio in non-metastatic and metastatic prostate cancer patients: a meta-analysis and systematic review","volume":"23","author":"Salciccia","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B51","doi-asserted-by":"publisher","first-page":"81","DOI":"10.7150\/jca.27210","article-title":"The hemoglobin, albumin, lymphocyte, and platelet (HALP) score is a novel significant prognostic factor for patients with metastatic prostate cancer undergoing cytoreductive radical prostatectomy","volume":"10","author":"Guo","year":"2019","journal-title":"J Cancer"},{"key":"B52","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1186\/s12943-024-02119-3","article-title":"Altered metabolism in cancer: insights into energy pathways and therapeutic targets","volume":"23","author":"Tufail","year":"2024","journal-title":"Mol Cancer"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.TR119000439","article-title":"Lipid rafts as signaling hubs in cancer cell survival\/death and invasion: implications in tumor progression and therapy. Thematic Review Series: Biology of Lipid Rafts","volume":"61","author":"Mollinedo","year":"2020","journal-title":"J Lipid Res"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.554078","article-title":"Endocrinology of the aging prostate: current concepts","volume":"12","author":"Cannarella","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B55","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s12894-023-01291-w","article-title":"Establishment and validation of serum lipid-based nomogram for predicting the risk of prostate cancer","volume":"23","author":"Feng","year":"2023","journal-title":"BMC Urol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000025602","article-title":"Based on biomedical index data: risk prediction model for prostate cancer","volume":"100","author":"Guo","year":"2021","journal-title":"Med (Baltimore)"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003859","article-title":"The relationship between lipoprotein A and other lipids with prostate cancer risk: a multivariable Mendelian randomization study","volume":"19","author":"Ioannidou","year":"2022","journal-title":"PloS Med"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1080\/01635581.2013.806936","article-title":"Serum calcium concentration and prostate cancer risk: a multicenter study","volume":"65","author":"Salem","year":"2013","journal-title":"Nutr Cancer"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.medcli.2016.12.021","article-title":"Severe hypocalcemia due to osteoblastic metastasis of prostate cancer","volume":"148","author":"Di\u00e9guez Felechosa","year":"2017","journal-title":"Med Clin (Barc)"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1007\/s10552-018-1081-5","article-title":"Mendelian randomization does not support serum calcium in prostate cancer risk","volume":"29","author":"Yarmolinsky","year":"2018","journal-title":"Cancer Causes Control"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1093\/ajcn\/nqab342","article-title":"Circulating phosphorus concentration and risk of prostate cancer: a Mendelian randomization study","volume":"115","author":"Lv","year":"2022","journal-title":"Am J Clin Nutr"},{"key":"B62","doi-asserted-by":"publisher","first-page":"705","DOI":"10.3390\/jpm13050705","article-title":"Biomarkers for prostate cancer bone metastasis detection and prediction","volume":"13","author":"Ying","year":"2023","journal-title":". J Pers Med"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.21037\/tcr.2019.05.08","article-title":"Prostate health index is useful for prostate cancer detecting in Chinese people","volume":"8","author":"Huang","year":"2019","journal-title":"Transl Cancer Res"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1599266\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T04:12:33Z","timestamp":1757909553000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1599266\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,15]]},"references-count":63,"alternative-id":["10.3389\/fonc.2025.1599266"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1599266","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,15]]},"article-number":"1599266"}}